News | December 31, 2023
Alkem completes sale of St. Louis manufacturing facility for US$ 7.96 million
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
Sirius JV will be owned 51% by Sirius and 49% by Adani
Marks remarkable acceleration in innovation using AI technology
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
The product is expected to be launched in December 2023
US FDA approval based on NEURO-TTRansform Phase III results
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
The plant is yet to start commercial operations
Subscribe To Our Newsletter & Stay Updated
